CA3237815A1 - Methods for enhancing adoptive cell transfer immunotherapies - Google Patents

Methods for enhancing adoptive cell transfer immunotherapies Download PDF

Info

Publication number
CA3237815A1
CA3237815A1 CA3237815A CA3237815A CA3237815A1 CA 3237815 A1 CA3237815 A1 CA 3237815A1 CA 3237815 A CA3237815 A CA 3237815A CA 3237815 A CA3237815 A CA 3237815A CA 3237815 A1 CA3237815 A1 CA 3237815A1
Authority
CA
Canada
Prior art keywords
igg
cells
protein
car
adoptive cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3237815A
Other languages
English (en)
French (fr)
Inventor
Raghuveer RANGANATHAN
Robert BOCKERMANN
Anna-Karin ROBERTSON
Christian Kjellman
Gianpietro Dotti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hansa Biopharma AB
Original Assignee
Hansa Biopharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hansa Biopharma AB filed Critical Hansa Biopharma AB
Publication of CA3237815A1 publication Critical patent/CA3237815A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01169—Protein O-GlcNAcase (3.2.1.169)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/2201—Streptopain (3.4.22.10)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3237815A 2021-11-15 2022-11-14 Methods for enhancing adoptive cell transfer immunotherapies Pending CA3237815A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163279398P 2021-11-15 2021-11-15
US63/279,398 2021-11-15
PCT/EP2022/081841 WO2023084095A2 (en) 2021-11-15 2022-11-14 Methods for enhancing adoptive cell transfer immunotherapies

Publications (1)

Publication Number Publication Date
CA3237815A1 true CA3237815A1 (en) 2023-05-19

Family

ID=84463039

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3237815A Pending CA3237815A1 (en) 2021-11-15 2022-11-14 Methods for enhancing adoptive cell transfer immunotherapies

Country Status (7)

Country Link
US (1) US20250325640A1 (enExample)
EP (1) EP4433587A2 (enExample)
JP (1) JP2024544565A (enExample)
CN (1) CN119013396A (enExample)
AU (1) AU2022385450A1 (enExample)
CA (1) CA3237815A1 (enExample)
WO (1) WO2023084095A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4739775A1 (en) * 2023-07-07 2026-05-13 Emory University Recombinant glycosidases, pharmaceutical compositions, and uses in managing autoimmune or inflammatory conditions
CN122438692A (zh) * 2023-08-01 2026-07-21 英斯梅德股份有限公司 新型IgG蛋白酶及其使用方法
CN120334552B (zh) * 2025-06-12 2025-09-12 成都蓉生药业有限责任公司 一种人免疫球蛋白对非人种属细胞的adcp活性的检测试剂的组合、检测试剂盒及其检测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164739A1 (en) * 2014-04-25 2015-10-29 Bluebird Bio, Inc. Kappa/lambda chimeric antigen receptors
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
CA3149395A1 (en) * 2019-08-01 2021-02-04 Memorial Sloan-Kettering Cancer Center Cells for improved immunotherapy and uses thereof
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods

Also Published As

Publication number Publication date
US20250325640A1 (en) 2025-10-23
EP4433587A2 (en) 2024-09-25
CN119013396A (zh) 2024-11-22
WO2023084095A2 (en) 2023-05-19
WO2023084095A3 (en) 2023-07-20
AU2022385450A1 (en) 2024-06-13
JP2024544565A (ja) 2024-12-03

Similar Documents

Publication Publication Date Title
US20250325640A1 (en) Methods for enhancing adoptive cell transfer immunotherapies
AU2018235130B2 (en) Method
EP2946791B1 (en) Anti-CD277 antibodies and uses thereof
JP7819119B2 (ja) 養子細胞移入免疫療法を増強する方法
CN110267978A (zh) 用于治疗癌症的表达膜锚定的il-12的t细胞
ES2928167T3 (es) Composiciones y métodos para reducir las respuestas inmunitarias contra receptores de antígenos quiméricos
CN112469479A (zh) 治疗癌症和自身免疫性疾病的试剂和方法
CN108884140A (zh) 修饰的嵌合受体及相关组合物和方法
JP2017537919A (ja) 養子細胞療法のための方法および組成物
JP2017519494A (ja) Ｏｘ４０ｌ融合タンパク質およびその使用
Singhal et al. Human tumor–associated macrophages and neutrophils regulate antitumor antibody efficacy through lethal and sublethal trogocytosis
HK1225998A1 (zh) 用於癌症治疗的包含抗ceacam1抗体和抗pd抗体的组合物
CA3174202A1 (en) Combination therapy involving anti-cd39 antibodies and adoptive cell therapy
US20240350630A1 (en) Compositions and methods of treating disease with chimeric antigen receptors to b cell maturation antigen (bcma)
Puri The Evaluation of MS4A4A and MS4A8B Expression in Hematopoietic Cells
Barney The functional consequences of IgA immune complex capture by FcRL4+ B cells
Jenkins Generating Protective Cancer Immunity by Allowing Nature to Lead the Way
TW202413412A (zh) 在組合療法中能夠結合到ｃｄ２７之結合劑
Solomon Targeting regulatory T cells for therapeutic gain in cancer therapy
CN119546315A (zh) 高效的过继性t细胞疗法
Hammond Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein Michael D. Oberst, Catherine Augé, Chad Morris, Stacy Kentner, Kathy Mulgrew, Kelly McGlinchey, James Hair, Shino Hanabuchi, Qun Du 2, Melissa Damschroder 2, Hui Feng 2, 10, Steven Eck 3, Nicholas Buss 4, Lolke de Haan 4, Andrew J. Pierce 5, Haesun Park 6, Andrew
HK1261193B (en) Compositions and methods for reducing immune responses against chimeric antigen receptors
HK1261193A1 (en) Compositions and methods for reducing immune responses against chimeric antigen receptors

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240930

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240930

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250923

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250923